BioSpace News Archive

Toxicity testing is one of the crucial steps in the drug development process. The side effects of a chemical substance on the body could lead to chronic health conditions and it could do more damage to the body than good.

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, its commercialization partner, have announced the first commercial patient has been implanted with Eversense® E3, kicking off the launch of the next-generation CGM System in the U.S.

IGM Biosciences, Inc. announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the underwriters of a 30-day option to purchase additional shares, 1,304,347 shares of its voting common stock, each at a price to the public of $23.00 per share.

The industry analysis report is considered a valuable source of information about the global Blood and Organ Bank industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The industry analysis report is considered a valuable source of information about the global Intra-Aortic Balloon Pump (IABP) industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

OMass Therapeutics is pleased to announce that its founder, Professor Dame Carol Robinson and her team, published a paper in Nature1 on the 6th of April.

Aspect Biosystems (“Aspect”), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

Magnolia Medical Technologies, Inc. announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System, clinically evaluating the impact of Steripath in reducing false-positive blood culture results throughout the hospital.

AmerisourceBergen, a global healthcare solutions company, today announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally.

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients are now published in the British Journal of Haematology.